M&TOD Earns Inaugural Impact Factor of 3.9, Ranked Q2 in Endocrinology & Metabolism

On June 18, 2025, Clarivate released the latest edition of the Journal Citation Reports (JCR). We are delighted to announce that Metabolism and Target Organ Damage (M&TOD) has achieved its first Impact Factor of 3.9, ranking 56th out of 191 journals in the Endocrinology & Metabolism category, placing it in Q2 (top 30%).

This milestone marks a significant achievement in M&TOD’s journey since its launch in September 2021, highlighting its rapid growth, increasing academic influence, and dedication to publishing high-quality, impactful research in the field of metabolism and organ-specific damage.

Currently indexed in ESCI and Scopus, M&TOD has shown a consistent upward trend in citations and global visibility. This success is a testament to the collective efforts and unwavering support of our vibrant academic community.

We extend our deepest gratitude to Editor-in-Chief Prof. Amedeo Lonardo, Honorary Editors Prof. Christopher D. Byrne and Prof. Giovanni Targher, and the entire international Editorial Board for their visionary leadership. We also thank our peer reviewers, contributing authors, and readers for their continued trust, contributions, and engagement.

Looking ahead, M&TOD remains committed to rigorous peer review, scientific excellence, and fostering innovation. We will continue to serve as a dynamic platform for the dissemination of cutting-edge research and global scholarly exchange.

Thank you to all who have supported M&TOD. We look forward to building on this success together.

Editor: Alani Luo
Language Editor: Catherine Yang
Production Editor: Ting Xu
Respectfully submitted by the Editorial Office of Metabolism and Target Organ Damage